Product/Composition:- | Luspatercept, |
---|---|
Strength:- | 25 mg, 75 mg |
Form:- | Lyophilized powder for subcutaneous injection |
Reference Brands:- | Reblozyl |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Luspatercept (Reblozyl) is an FDA and EMA-approved biologic used to treat anemia in beta thalassemia and MDS patients. It reduces transfusion needs by enhancing red blood cell production. Offered in GMP-certified form, ideal for pharma B2B buyers, distributors, and exporters. Contact us for bulk supply and regulatory support.
Luspatercept is a groundbreaking erythroid maturation agent used to treat anemia in patients with beta thalassemia and myelodysplastic syndromes (MDS). Marketed under the brand name Reblozyl, it is approved by the FDA and EMA for reducing red blood cell transfusion dependence. Luspatercept is a recombinant fusion protein administered via subcutaneous injection and produced under strict GMP compliance. Ideal for pharmaceutical distributors, wholesalers, and B2B partners seeking high-demand biologics. We offer global bulk supply, regulatory support, and competitive pricing for Luspatercept. Partner with us for reliable sourcing and efficient delivery. Contact us now for Luspatercept export and distribution solutions.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications